Clinical applications for the endotoxin activity assay in sepsis: a scoping review - Takeaways - MDSpire

Clinical applications for the endotoxin activity assay in sepsis: a scoping review

  • By

  • Yohei Komaru

  • Akinori Maeda

  • Ryota Inokuchi

  • Debra M. Foster

  • John A. Kellum

  • Kent Doi

  • January 30, 2026

  • 0 min

Share

  • 1

    Sepsis affects 50 million people annually, contributing to one in five global deaths, highlighting its critical health impact.

  • 2

    The Endotoxin Activity Assay (EAA) offers rapid and specific detection of endotoxin activity, improving upon traditional methods like the LAL assay.

  • 3

    EAA results do not always correlate with LAL results, and elevated levels can occur in patients without Gram-negative infections.

  • 4

    Clinical interpretation of EAA values remains controversial, with proposed cut-off values varying and lacking consensus on their clinical implications.

  • 5

    The study aims to systematically review EAA applications in sepsis, identifying trends and knowledge gaps for its future use in precision medicine.

Original Source(s)

Clinical applications for the endotoxin activity assay in sepsis: a scoping review

  • by Yohei Komaru, Akinori Maeda, Ryota Inokuchi, Debra M. Foster, John A. Kellum, Kent Doi

  • January 30, 2026

Related Content

Formation of biofilms on venovenous ECMO cannulas may facilitate pathogen reintroduction during decannulation: Insights from a small-scale study integrating culture and molecular data.

Exploratory Study of Bioactive Adrenomedullin as a Potential Biomarker for Severe Infections in Emergency Department Patients

Is Your AI Tool Clinically Ready?

Bobbi Pritt on validation evidence, bias, interoperability, and why workflow integration matters most